Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 in type 2 diabetes mellitus
NCT06777238Phase 3Active, not recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bofanglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Glycated Hemoglobin at 44 weeks. Started Jan 2025; status: active, not recruiting.
02
Drugs
bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06777238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777238.